SCHEMBL6419626

SCHEMBL6419626

Oc1c(Br)cc(Br)cc1C=NNc1nc2nonc2nc1Nc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 14/20 0.47
KMT2A Q03164 14/20 0.47
MAPT P10636 12/20 0.47
SMN1; SMN2 Q16637 7/20 0.47
KDM4E B2RXH2 6/20 0.47
POLB P06746 4/20 0.47
ALDH1A1 P00352 2/20 0.47
HSP90AA1 P07900 1/20 0.47
PPARG P37231 1/20 0.47
BLM P54132 1/20 0.47
NCOA2 Q15596 1/20 0.47
RAB9A P51151 6/20 0.43
NPC1 O15118 4/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.42
GFER P55789 1/20 0.42
LMNA P02545 4/20 0.41
HTT P42858 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414734 0.90 MEN1 (0.48) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL6432678 0.90 MEN1 (0.51) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL6417091 0.88 ERN1 (0.40) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL6412900 0.88 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL6417086 0.88 ERN1 (0.40) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL13310234 0.87 KMT2A (0.47) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL6418385 0.87 KMT2A (0.47) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL6415083 0.83 MEN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL6417232 0.81 DDX3X (0.49) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL6421066 0.80 KMT2A (0.54) MEN1KMT2AMAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MEN1 4392/4885KMT2A 3640/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.